title: Temozolomide treatment of refractory epilepsy in a patient with an oligodendroglioma.
abstract: A 40-year-old man with a left frontotemporal grade II oligodendroglioma developed seizures that were refractory to 14 antiepileptic medications, the ketogenic diet, and epilepsy surgery. With temozolomide therapy, his seizure frequency gradually changed from 30 partial seizures per day to a single simple partial seizure in 6 months. No additional therapeutic measures were introduced during this time. This reduction in seizure frequency appears attributable solely to temozolomide therapy.
authors.affiliation: Jefferson Comprehensive Epilepsy Center, Philadelphia, PA 19107, USA.
authors.forename: Ly
authors.initials: L
authors.lastname: Ngo
authors.forename: Maromi
authors.initials: M
authors.lastname: Nei
authors.forename: Jon
authors.initials: J
authors.lastname: Glass
mesh_terms: D000328:Adult; D000927:Anticonvulsants / Q000627:therapeutic use; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D015897:Comorbidity; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004351:Drug Resistance; D004827:Epilepsy / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D009837:Oligodendroglioma / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D000077204:Temozolomide; D016896:Treatment Outcome
chemical_list: D000927:Anticonvulsants; D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide